PBAC's latest decision on Budesonide with eformoterol fumarate dihydrate: Recommended with restriction (2017). Considered for Asthma in patients aged 18 years and over with frequent episodes or symptoms despite treatment with oral corticosteroids, inhaled corticosteroids, or combination ICS/LABA therapy. Also indicated for COPD in patients aged 18 years and over with FEV1 <50% predicted and repeated exacerbations despite regular beta-2 agonist therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
6
first 2007
Submissions
6
2007 → 2017
Eligible population
Adults aged 18 years and over with asthma who have experienced frequent episodes or symptoms despite treatment with oral corticosteroids, inhaled corticosteroids, or combination ICS/LABA therapy; or adults with COPD aged 18 years and over with FEV1 <50% predicted and repeated exacerbations despite regular beta-2 agonist therapy.
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Symbicort Turbuhaler
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission requested cost minimisation to currently listed Symbicort Turbuhaler formulations.
Submission history
Mar 2007: Recommended with restriction · Restricted
Nov 2010: Recommended with restriction · Restricted Benefit
Jul 2013: Recommended · Restricted
Jul 2017: Not recommended · Restricted
Nov 2017: Recommended with restriction · Restricted
Nov 2017: Recommended with restriction · Authority Required